News Johnson & Johnson Mexican S.E.

Equities

JNJ *

US4781601046

End-of-day quote Mexican S.E. Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
2,709 ^MXN	+3.40%		+8.80%	+2.39%

12:18am	Top law firms in US opioid lawsuits to get hundreds of millions in fees	RE
06-07	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top law firms in US opioid lawsuits to get hundreds of millions in fees	06:18pm	RE
J&J-backed Rapport Therapeutics shares debut nearly 6% higher	06-07	RE
Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	06-07	PU
J&J: FDA approves VELYS for knee arthroplasty	06-07	CF
AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07	RE
J&J-backed Rapport Therapeutics raises $136 mln in US IPO	06-06	RE
Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	06-06	MT
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	06-05	AQ
J&J: applies to FDA for expanded indication for Prezcobix	06-05	CF
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	06-04	BU
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	06-04
J&J: successful trial for Carvykti in multiple myeloma	06-04	CF
J&J: promising trial for Tecvayli in multiple myeloma	06-04	CF
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	06-04	PU
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	06-04	MT
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	06-04	AQ
J&J must pay $260 million in latest talc trial, Oregon jury says	06-03	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	06-03	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	06-03	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	06-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm